Welcome to our dedicated page for KEWAUNEE SCIENTIFIC /DE/ SEC filings (Ticker: KEQU), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on KEWAUNEE SCIENTIFIC /DE/'s stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into KEWAUNEE SCIENTIFIC /DE/'s regulatory disclosures and financial reporting.
Kewaunee Scientific Corporation will hold its 2026 Annual Meeting virtually on August 26, 2026 at 11:00 a.m. Eastern Time. Stockholders will vote on electing three Class I directors to serve until the 2029 meeting, ratifying Forvis Mazars, LLP as independent auditor for fiscal 2027, and approving on an advisory basis the compensation of named executive officers.
The Board is majority independent, with separate Chair and CEO roles and active Audit, Compensation, Financial/Planning, and Nominating and Corporate Governance Committees. Non-employee directors received a $120,000 annual retainer in fiscal 2026, generally half in cash and half in fully vested stock, plus additional cash fees for committee and Board leadership roles.
Executive pay combines base salary, annual incentives tied mainly to EBITDA and non-financial objectives, and long-term incentives in time- and performance-based RSUs under the 2023 Omnibus Incentive Plan. For fiscal 2026, CEO Thomas D. Hull III had base salary of $526,190 and total compensation of $1,965,495, including a $394,967 cash bonus. The company reports net income of $9.618 million in 2026 and a Company Total Shareholder Return value of $227.75 on an initial $100 investment over the three-year measurement period.
Kewaunee Scientific senior vice president of People & Culture Elizabeth D. Phillips reported compensation-related stock transactions. On June 30, 2026, she exercised restricted stock units, acquiring 6,656 shares of common stock. Of these, 793 shares were withheld at $36.25 per share to cover tax obligations.
Footnotes state that performance-based RSUs vested at 150% of target, with RSUs otherwise entitling her to 4,995 shares settled in cash through a disposition to the issuer at $36.25 per share, while 475 service-based RSUs delivered 475 shares. After these transactions, she directly holds 9,116 shares of common stock.
Kewaunee Scientific senior vice president of IT & Engineering Mandar Ranade reported several equity compensation transactions dated June 30, 2026. He exercised awards to acquire 7,227 shares of common stock at a stated price of $0.0000 per share, tied to vested restricted stock units. Footnotes explain that 4,159 shares were delivered upon settlement of service- and performance-based RSUs, while an additional portion of performance-based RSUs was settled in cash in lieu of 1,800 shares. To cover obligations, 1,877 shares were disposed of at $36.25 per share as a tax-withholding transaction and 1,800 shares were returned to the company at the same price as a disposition to the issuer. After these moves, Ranade directly holds 16,215 shares of common stock.
Kewaunee Scientific senior vice president of sales and marketing development Ryan S. Noble reported several equity compensation transactions in the company’s common stock. On June 30, 2026, he exercised awards to acquire 7,206 shares of common stock, primarily from vested restricted stock units. To cover obligations tied to this settlement, 1,809 shares were used in a tax-withholding disposition at $36.25 per share, and 3,000 shares were delivered back to the issuer as a disposition to the company at the same price. After these transactions, Noble directly held 16,240 shares of common stock. He also continued to hold unvested or unsettled restricted stock units from more recent grants, including FY25 and FY26 awards that are subject to service-based and performance-based vesting conditions.
Kewaunee Scientific senior vice president of manufacturing operations Douglas J. Batdorff reported a set of compensation-related equity transactions. On June 30, 2026, he acquired 7,451 shares of common stock through the settlement of restricted stock units, while 851 shares were withheld to cover tax obligations and 5,609 shares were disposed of back to the company for cash instead of receiving shares. Footnotes note that 3,739 performance-based RSUs vested at 150% of target and 535 service-based RSUs vested the same day.
Kewaunee Scientific Chief Financial Officer Donald T. Gardner III reported a series of equity compensation events on June 30, 2026. He exercised and settled various restricted stock units into common stock, including performance-based RSUs that vested at 150% of target. As part of the settlement, 4,027 shares of common stock at $36.25 per share were withheld to cover tax obligations, and 12,000 shares were delivered to the company pursuant to his prior election for cash settlement. Footnotes state that, in total, 11,397 performance-based RSUs were settled and 6,723 shares were received from RSU settlements, along with a cash payment in lieu of additional shares.
Kewaunee Scientific President and CEO Thomas David Hull III reported several compensation-related share transactions tied to restricted stock units. On June 30, 2026, he exercised or settled awards to acquire common stock and used part of the shares to cover obligations.
Hull exercised or settled awards covering 54,388 shares of common stock. Of these, 16,243 shares were delivered at $36.25 per share to satisfy tax obligations, and 17,000 shares were disposed to the issuer for cash under his election. Footnotes state that service- and performance-based RSUs convert one-for-one into common stock.
Footnotes also explain that 28,929 performance-based RSUs were settled at 150% of target, resulting in 26,393 shares plus cash in lieu of 17,000 shares, and 4,132 service-based RSUs vested. Overall, the filing reflects routine equity compensation vesting, tax withholding, and related dispositions rather than open-market trading.
Kewaunee Scientific Corporation ownership disclosure: Minerva Advisors LLC, Minerva Group LP, Minerva GP, LP, Minerva GP, Inc., and David P. Cohen report beneficial ownership stakes in the issuer's common stock.
The filing states specific holdings: Minerva Advisors LLC and David P. Cohen are each shown as beneficial owners of 149,410 shares (5.2%), while Minerva Group LP, Minerva GP, LP and Minerva GP, Inc. each hold 103,167 shares (3.6%). The filing cites 2,870,410 shares outstanding as of 6/24/2026 from the issuer's Form 10-K.
Kewaunee Scientific Corporation reports fiscal 2026 results showing net sales of $281.999 million, up from $240.472 million, driven largely by the November 2024 acquisition of Nu Aire. Lab Products Group sales reached $214.9 million and International segment sales were $67.1 million.
Gross margin was 28.5% of sales, essentially flat year over year, while operating expenses rose to $63.7 million, reflecting Nu Aire integration and higher corporate costs, including Sarbanes-Oxley 404(b) readiness. Net earnings attributable to Kewaunee declined to $9.618 million, or $3.22 per diluted share, from $11.405 million, or $3.83 per diluted share.
Order backlog decreased to $165.9 million at April 30, 2026 from $214.6 million, with Lab Products Group backlog at $118.8 million and International at $47.1 million. Cash from operations was $18.6 million, term loans totaled $20.1 million, and management believes current liquidity and its $20 million revolving credit facility support capital needs through fiscal 2027.